Table 1.
Feature of included studies
| Author, year | Country | Predesign | Number of participants | TIV/PVT | Age | Gender (male/female) | Medical history | Reference standard | Contrast agents |
|---|---|---|---|---|---|---|---|---|---|
| Norio Ueno, 2006 | Japan | Prospective, but blind not mentioned | 55 | 40/15 | 66 (53–83) | 43/12 | Chronic liver diseases | Pathology, CT or angiography follow-up | Levovist |
| Paolo Sorrentino, 2009 | Italy | Prospective, blind | 108 | 58/50 | 66 ± 6 | 82/26 | Cirrhosis with HCC | Pathology (biopsy) and follow-up | SonoVue |
| Ze-Zhou Song, 2010 | China | Prospective, blind | 17 | 14/3 | 38–78 | 14/3 | Cirrhosis with HCC | Pathology and follow-up | SonoVue |
| Sandro Rossi, 2008 | Italy | Prospective, blind | 50 | 44/6 | 67 ± 5 | 39/11 | Cirrhosis with HCC | Pathology | SonoVue |
| Paolo Sorrentino, 2011 | Italy | Prospective, blind | 96 | 72/24 | 66 (43–88) | 61/35 | Cirrhosis with HCC | Pathology | SonoVue |
| Maria C Chammas, 2019 | Brazil | Prospective, blind | 43 | 22/21 | 64 (51–77) | 31/12 | Chronic liver diseases and HCC-suggestive nodules | > 6 months imaging follow-up | PESDA, Definity, or SonoVue |
| P. RiCCI, 2000 | Italy | Not mentioned | 56 | 16/40 | 57 (47–79) | 39/17 | Cirrhosis | Pathology and CT/MRI imaging | Levovist |
TIV, tumor-in-vein; PVT, portal vein thrombosis; HCC, hepatocellular carcinoma